Signal Advisors Wealth LLC Purchases Shares of 5,339 United Therapeutics Corporation $UTHR

Key Points

• Signal Advisors Wealth LLC has invested approximately $1.53 million in United Therapeutics by acquiring 5,339 shares, reflecting growing interest from institutional investors in the biotechnology sector.
• Equities analysts have recently increased their price targets for United Therapeutics, with estimates ranging from $330 to $564, suggesting a positive outlook for the company's stock.
• Insider selling has occurred at United Therapeutics, with notable transactions including the COO selling 22,500 shares for over $9 million, raising concerns about insider confidence in the company's future.

Signal Advisors Wealth LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,339 shares of the biotechnology company's stock, valued at approximately $1,534,000.

A number of other large investors have also recently bought and sold shares of the company. SVB Wealth LLC acquired a new position in United Therapeutics in the first quarter valued at approximately $32,000. Geneos Wealth Management Inc. raised its stake in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after buying an additional 85 shares during the period. Sound Income Strategies LLC acquired a new position in shares of United Therapeutics during the 1st quarter worth approximately $49,000. Brooklyn Investment Group raised its stake in shares of United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock worth $59,000 after buying an additional 98 shares during the period. Finally, WPG Advisers LLC acquired a new position in shares of United Therapeutics during the 1st quarter worth approximately $60,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on UTHR shares. Morgan Stanley reduced their target price on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Jefferies Financial Group increased their price objective on United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. Cantor Fitzgerald increased their price objective on United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research note on Wednesday, September 10th. Oppenheimer increased their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a research note on Friday, September 5th. Finally, Bank of America increased their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a research note on Tuesday, September 2nd. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $438.85.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $385.21, for a total value of $4,237,310.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $14,168,409.01. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 172,116 shares of company stock valued at $63,256,557. Insiders own 10.30% of the company's stock.

United Therapeutics Stock Up 1.9%

NASDAQ:UTHR traded up $7.70 during mid-day trading on Friday, reaching $417.57. 1,940,191 shares of the stock were exchanged, compared to its average volume of 874,340. The company has a 50 day simple moving average of $329.55 and a 200-day simple moving average of $310.67. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $436.95. The stock has a market capitalization of $18.84 billion, a P/E ratio of 16.30, a P/E/G ratio of 6.37 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm's quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter last year, the firm earned $5.85 earnings per share. As a group, research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.